Clinical trial results:
A Phase 1/2, Open-label Randomized Study of Ulocuplumab (BMS-936564) In Combination with Low Dose Cytarabine in Subjects with Newly Diagnosed Acute Myeloid Leukemia

Summary

EudraCT number	2016-004275-40
Trial protocol	RO
Global end of trial date	04 June 2019

Results information

Result version number	v1 (current)
This version publication date	05 July 2020
First version publication date	05 July 2020

Trial information

Trial identification

Sponsor protocol code	CA212-016

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Bristol-Myers Squibb
Sponsor organisation address	Chaussée de la Hulpe 185, Brussels, Belgium, 1170
Public contact	Bristol-Myers Squibb International Corporation, EU Study Start-Up Unit, Clinical.Trials@bms.com
Scientific contact	Bristol-Myers Squibb Study Director, Bristol-Myers Squibb, Clinical.Trials@bms.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	10 September 2019
Is this the analysis of the primary completion data?	Yes
Primary completion date	04 June 2019
Global end of trial reached?	Yes
Global end of trial date	04 June 2019
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

In Phase 1 (escalation cohort): To assess the safety and tolerability of ulocuplumab in combination with low-dose cytarabine (LDAC) in participants with AML. In Phase 2 (expansion cohort): To estimate preliminary efficacy in terms of complete remission (CR/CRi=CR+CRi) in participants treated at two different dose levels of ulocuplumab, 800 mg and 1000 mg, in combination with low-dose cytarabine (LDAC).

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Conference on Harmonization Good Clinical Practice Guidelines. All the local regulatory requirements pertinent to safety of trial participants were followed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	10 April 2015
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Brazil: 5
Country: Number of subjects enrolled	Israel: 5
Country: Number of subjects enrolled	Italy: 5
Country: Number of subjects enrolled	Japan: 22
Country: Number of subjects enrolled	Korea, Republic of: 3
Country: Number of subjects enrolled	Taiwan: 6
Country: Number of subjects enrolled	United States: 24
Worldwide total number of subjects	70
EEA total number of subjects	5

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0

Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	0
From 65 to 84 years	68
85 years and over	2

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

6 participants in Phase 1 and 64 participants in Phase 2 (70 in total) were assigned to treatment. 2 participants randomized to the LDAC-only arm in Phase 2 did not receive treatment. 68 participants in total (phases 1 and 2) were treated.

Period 1

Period 1 title	Treatment Period
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	No
Arm title	ULO 600mg + LDAC - Ph1

Arm description:

Ulocuplumab (ULO) at 600mg + low dose cytarabine (LDAC) - Phase 1 (Ph1)

Arm type	Experimental
Investigational medicinal product name	ulocuplumab; LDAC
Investigational medicinal product code	
Other name	BMS-936564; low dose cytarabine
Pharmaceutical forms	Injection
Routes of administration	Intravenous use, Subcutaneous use

Dosage and administration details:

600mg for ulocuplumab; 20 mg BID for LDAC

Arm title	ULO 800mg + LDAC - Ph1

Arm description:

Ulocuplumab (ULO) at 800mg + low dose cytarabine (LDAC) - Phase 1 (Ph1)

Arm type	Experimental
Investigational medicinal product name	ulocuplumab; LDAC
Investigational medicinal product code	
Other name	BMS-936564; low dose cytarabine
Pharmaceutical forms	Injection
Routes of administration	Intravenous use, Subcutaneous use

Dosage and administration details:

800mg for ulocuplumab; 20 mg BID for LDAC

Arm title	ULO 800mg + LDAC - Ph2

Arm description:

Ulocuplumab (ULO) at 800mg + low dose cytarabine (LDAC) - Phase 2 (Ph2)

Arm type	Experimental
Investigational medicinal product name	ulocuplumab; LDAC
Investigational medicinal product code	
Other name	BMS-936564; low dose cytarabine
Pharmaceutical forms	Injection
Routes of administration	Intravenous use, Subcutaneous use

Dosage and administration details:

800mg for ulocuplumab; 20 mg BID for LDAC

Arm title	ULO 1000mg + LDAC - Ph2
Arm description: Ulocuplumab (ULO) at 1000mg + low dose cytarabine (LDAC) - Phase 2 (Ph2)	
Arm type	Experimental
Investigational medicinal product name	ulocuplumab; LDAC
Investigational medicinal product code	
Other name	BMS-936564; low dose cytarabine
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use
Dosage and administration details: 1000mg for ulocuplumab; 20 mg BID for LDAC	
Arm title	LDAC - Ph2
Arm description: Low dose cytarabine (LDAC) - Phase 2 (Ph2)	
Arm type	Active comparator
Investigational medicinal product name	LDAC
Investigational medicinal product code	
Other name	low dose cytarabine
Pharmaceutical forms	Injection
Routes of administration	Intravenous use, Subcutaneous use
Dosage and administration details: 20 mg BID for LDAC	

Number of subjects in period 1	ULO 600mg + LDAC - Ph1	ULO 800mg + LDAC - Ph1	ULO 800mg + LDAC - Ph2
Started	3	3	26
Completed	1	1	1
Not completed	2	2	25
Adverse event, serious fatal	-	-	-
Disease progression	-	-	15
Administrative reason by Sponsor	-	-	-
Participant withdrew consent	-	-	1
Maximum clinical benefit	-	-	-
Participant request to stop therapy	-	2	-
added ULO; then other reason	-	-	-
other reason	2	-	2
Adverse Event (AE) unrelated to drug	-	-	7
added ULO, then disease progression	-	-	-
added ULO, then request to stop	-	-	-
Study drug toxicity	-	-	-
Randomized but not treated	-	-	-
Poor/non-compliance	-	-	-

Number of subjects in period 1	ULO 1000mg + LDAC - Ph2	LDAC - Ph2
Started	14	24
Completed	0	0
Not completed	14	24
Adverse event, serious fatal	2	1
Disease progression	6	6
Administrative reason by Sponsor	-	1
Participant withdrew consent	1	1
Maximum clinical benefit	-	1
Participant request to stop therapy	1	-
added ULO; then other reason	-	1
other reason	2	1
Adverse Event (AE) unrelated to drug	1	2
added ULO, then disease progression	-	4
added ULO, then request to stop	-	1
Study drug toxicity	1	2
Randomized but not treated	-	2
Poor/non-compliance	-	1

Period 2	
Period 2 title	Follow-up Period
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms	
Are arms mutually exclusive?	Yes
Arm title	ULO 600mg + LDAC - Ph1
Arm description: Ulocuplumab (ULO) at 600mg + low dose cytarabine (LDAC) - Phase 1 (Ph1)	
Arm type	Experimental
Investigational medicinal product name	ulocuplumab; LDAC
Investigational medicinal product code	
Other name	BMS-936564; low dose cytarabine
Pharmaceutical forms	Injection
Routes of administration	Intravenous use, Subcutaneous use
Dosage and administration details: 600mg for ulocuplumab; 20 mg BID for LDAC	
Arm title	ULO 800mg + LDAC - Ph1
Arm description: Ulocuplumab (ULO) at 800mg + low dose cytarabine (LDAC) - Phase 1 (Ph1)	
Arm type	Experimental

Investigational medicinal product name	ulocuplumab; LDAC
Investigational medicinal product code	
Other name	BMS-936564; low dose cytarabine
Pharmaceutical forms	Injection
Routes of administration	Intravenous use, Subcutaneous use

Dosage and administration details:
800mg for ulocuplumab; 20 mg BID for LDAC

Arm title	ULO 800mg + LDAC - Ph2

Arm description:
Ulocuplumab (ULO) at 800mg + low dose cytarabine (LDAC) - Phase 2 (Ph2)

Arm type	Experimental
Investigational medicinal product name	ulocuplumab; LDAC
Investigational medicinal product code	
Other name	BMS-936564; low dose cytarabine
Pharmaceutical forms	Injection
Routes of administration	Intravenous use, Subcutaneous use

Dosage and administration details:
800mg for ulocuplumab; 20 mg BID for LDAC

Arm title	ULO 1000mg + LDAC - Ph2

Arm description:
Ulocuplumab (ULO) at 1000mg + low dose cytarabine (LDAC) - Phase 2 (Ph2)

Arm type	Experimental
Investigational medicinal product name	ulocuplumab; LDAC
Investigational medicinal product code	
Other name	BMS-936564; low dose cytarabine
Pharmaceutical forms	Injection
Routes of administration	Subcutaneous use

Dosage and administration details:
1000mg for ulocuplumab; 20 mg BID for LDAC

Arm title	LDAC - Ph2

Arm description:
Low dose cytarabine (LDAC) - Phase 2 (Ph2)

Arm type	Active comparator
Investigational medicinal product name	LDAC
Investigational medicinal product code	
Other name	low dose cytarabine
Pharmaceutical forms	Injection
Routes of administration	Intravenous use, Subcutaneous use

Dosage and administration details:
20 mg BID for LDAC

Number of subjects in period 2	ULO 600mg + LDAC - Ph1	ULO 800mg + LDAC - Ph1	ULO 800mg + LDAC - Ph2
Started	1	1	11
Completed	1	1	0
Not completed	0	0	11
Adverse event, serious fatal	-	-	5

Participant withdrew consent	-	-	2
Followup no longer required per protocol	-	-	4
other reason	-	-	-

Number of subjects in period 2	ULO 1000mg + LDAC - Ph2	LDAC - Ph2
Started	6	12
Completed	0	0
Not completed	6	12
Adverse event, serious fatal	4	7
Participant withdrew consent	1	-
Followup no longer required per protocol	1	4
other reason	-	1

Baseline characteristics

Reporting groups	
Reporting group title	ULO 600mg + LDAC - Ph1
Reporting group description:	
Ulocuplumab (ULO) at 600mg + low dose cytarabine (LDAC) - Phase 1 (Ph1)	
Reporting group title	ULO 800mg + LDAC - Ph1
Reporting group description:	
Ulocuplumab (ULO) at 800mg + low dose cytarabine (LDAC) - Phase 1 (Ph1)	
Reporting group title	ULO 800mg + LDAC - Ph2
Reporting group description:	
Ulocuplumab (ULO) at 800mg + low dose cytarabine (LDAC) - Phase 2 (Ph2)	
Reporting group title	ULO 1000mg + LDAC - Ph2
Reporting group description:	
Ulocuplumab (ULO) at 1000mg + low dose cytarabine (LDAC) - Phase 2 (Ph2)	
Reporting group title	LDAC - Ph2
Reporting group description:	
Low dose cytarabine (LDAC) - Phase 2 (Ph2)	

Reporting group values	ULO 600mg + LDAC - Ph1	ULO 800mg + LDAC - Ph1	ULO 800mg + LDAC - Ph2
Number of subjects	3	3	26
Age Categorical			
Age categorical			
Units: Participants			
<70	1	0	4
>=70	2	3	22
Age Continuous			
Units: Years			
arithmetic mean	73.7	77.3	74.9
standard deviation	± 8.02	± 1.53	± 5.4
Sex: Female, Male			
Units: Participants			
Female	3	0	9
Male	0	3	17
Race/Ethnicity, Customized			
Race			
Units: Subjects			
White	0	0	15
Black/African American	0	0	0
Japanese	3	3	6
Chinese	0	0	2
Asian Indian	0	0	0
Asian Other	0	0	3
American Indian/Alaskan Native	0	0	0
Native Hawaiian/Other Pacific Islander	0	0	0
Other	0	0	0
Ethnicity (NIH/OMB)			
Units: Subjects			

Hispanic or Latino	0	0	0
Not Hispanic or Latino	0	0	0
Unknown or Not Reported	3	3	26

Reporting group values	ULO 1000mg + LDAC - Ph2	LDAC - Ph2	Total
Number of subjects	14	24	70
Age Categorical			
Age categorical			
Units: Participants			
<70	3	3	11
>=70	11	21	59
Age Continuous			
Units: Years			
arithmetic mean	73.1	75.9	
standard deviation	± 3.7	± 5.7	-
Sex: Female, Male			
Units: Participants			
Female	7	14	33
Male	7	10	37
Race/Ethnicity, Customized			
Race			
Units: Subjects			
White	4	12	31
Black/African American	0	0	0
Japanese	6	4	22
Chinese	2	3	7
Asian Indian	0	0	0
Asian Other	0	2	5
American Indian/Alaskan Native	1	0	1
Native Hawaiian/Other Pacific Islander	0	0	0
Other	1	3	4
Ethnicity (NIH/OMB)			
Units: Subjects			
Hispanic or Latino	0	0	0
Not Hispanic or Latino	0	0	0
Unknown or Not Reported	14	24	70

End points

End points reporting groups

Reporting group title	ULO 600mg + LDAC - Ph1
Reporting group description: Ulocuplumab (ULO) at 600mg + low dose cytarabine (LDAC) - Phase 1 (Ph1)	
Reporting group title	ULO 800mg + LDAC - Ph1
Reporting group description: Ulocuplumab (ULO) at 800mg + low dose cytarabine (LDAC) - Phase 1 (Ph1)	
Reporting group title	ULO 800mg + LDAC - Ph2
Reporting group description: Ulocuplumab (ULO) at 800mg + low dose cytarabine (LDAC) - Phase 2 (Ph2)	
Reporting group title	ULO 1000mg + LDAC - Ph2
Reporting group description: Ulocuplumab (ULO) at 1000mg + low dose cytarabine (LDAC) - Phase 2 (Ph2)	
Reporting group title	LDAC - Ph2
Reporting group description: Low dose cytarabine (LDAC) - Phase 2 (Ph2)	
Reporting group title	ULO 600mg + LDAC - Ph1
Reporting group description: Ulocuplumab (ULO) at 600mg + low dose cytarabine (LDAC) - Phase 1 (Ph1)	
Reporting group title	ULO 800mg + LDAC - Ph1
Reporting group description: Ulocuplumab (ULO) at 800mg + low dose cytarabine (LDAC) - Phase 1 (Ph1)	
Reporting group title	ULO 800mg + LDAC - Ph2
Reporting group description: Ulocuplumab (ULO) at 800mg + low dose cytarabine (LDAC) - Phase 2 (Ph2)	
Reporting group title	ULO 1000mg + LDAC - Ph2
Reporting group description: Ulocuplumab (ULO) at 1000mg + low dose cytarabine (LDAC) - Phase 2 (Ph2)	
Reporting group title	LDAC - Ph2
Reporting group description: Low dose cytarabine (LDAC) - Phase 2 (Ph2)	

Primary: Number of participants with Dose-Limiting Toxicities (DLTs) in treatment cycle 1 - Phase 1

End point title	Number of participants with Dose-Limiting Toxicities (DLTs) in treatment cycle 1 - Phase 1[1][2]
End point description: Safety data evaluated for DLTs. DLTs and all other toxicities were defined and evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 (NCI CTCAE v4.03). DLTs were defined based upon events that were considered to be related to ulocuplumab in combination with LDAC and that occurred during the first cycle of drug administration (28 days). Note: an entry of "9999" is equivalent to "NA" (not available).	
End point type	Primary
End point timeframe: From first dose to end of cycle 1 (28 days)	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Only summary statistics were planned for this endpoint

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Only phase 1 summary statistics were planned for this endpoint

End point values	ULO 600mg + LDAC - Ph1	ULO 800mg + LDAC - Ph1		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3	3		
Units: Participants	9999	9999		

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with Adverse Events (AEs) - Phase 1

End point title	Number of participants with Adverse Events (AEs) - Phase

End point description:

The number of participants with an on-study adverse event (AE). Safety data are evaluated for AEs, defined and evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 (NCI CTCAE v4.03).

End point type	Primary

End point timeframe:

From first dose to 30 days post last dose

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Only summary statistics were planned for this endpoint

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Only phase 1 summary statistics were planned for this endpoint

End point values	ULO 600mg + LDAC - Ph1	ULO 800mg + LDAC - Ph1		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3	3		
Units: Participants	3	3		

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with >= Grade 3 AEs - Phase 1

End point title	Number of participants with >= Grade 3 AEs - Phase 1[5][6]

End point description:

The number of participants with an on-study adverse event >= Grade level 3. Safety data are evaluated

for >= Grade 3 AEs, defined and evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 (NCI CTCAE v4.03).

End point type	Primary

End point timeframe:

From first dose to 30 days post last dose

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Only summary statistics were planned for this endpoint

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Only phase 1 summary statistics were planned for this endpoint

End point values	ULO 600mg + LDAC - Ph1	ULO 800mg + LDAC - Ph1		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3	3		
Units: Participants	3	3		

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with AEs leading to discontinuation - Phase 1

End point title	Number of participants with AEs leading to discontinuation - Phase 1[7][8]

End point description:

The number of participants with an on-study adverse event (AE) leading to discontinuation. Safety data are evaluated for AEs leading to discontinuation, defined and evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 (NCI CTCAE v4.03).

End point type	Primary

End point timeframe:

From first dose to 30 days post last dose

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Only summary statistics were planned for this endpoint

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Only phase 1 summary statistics were planned for this endpoint

End point values	ULO 600mg + LDAC - Ph1	ULO 800mg + LDAC - Ph1		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3	3		
Units: Participants	0	0		

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with Serious Adverse Events (SAEs) - Phase 1

End point title	Number of participants with Serious Adverse Events (SAEs) - Phase 1[9][10]

End point description:

The number of participants with an on-study serious adverse event (SAE). Safety data are evaluated for SAEs, defined and evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 (NCI CTCAE v4.03).

End point type	Primary

End point timeframe:

From first dose to 30 days post last dose

Notes:

[9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Only summary statistics were planned for this endpoint

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Only phase 1 summary statistics were planned for this endpoint

End point values	ULO 600mg + LDAC - Ph1	ULO 800mg + LDAC - Ph1		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3	3		
Units: Participants	2	1		

Statistical analyses

No statistical analyses for this end point

Primary: Number of deaths - Phase 1

End point title	Number of deaths - Phase 1[11][12]

End point description:

The number of participants who died.

End point type	Primary

End point timeframe:

From first dose to 30 days post last dose

Notes:

[11] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Only summary statistics were planned for this endpoint

[12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Only phase 1 summary statistics were planned for this endpoint

End point values	ULO 600mg + LDAC - Ph1	ULO 800mg + LDAC - Ph1		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3	3		
Units: Participants	0	0		

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with laboratory abnormalities - Phase 1

End point title	Number of participants with laboratory abnormalities - Phase

End point description:

The number of participants with an on-study laboratory abnormality. Safety data are evaluated for laboratory abnormalities, defined and evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 (NCI CTCAE v4.03).

End point type	Primary

End point timeframe:

From first dose to 30 days post last dose

Notes:

[13] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Only summary statistics were planned for this endpoint

[14] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Only phase 1 summary statistics were planned for this endpoint

End point values	ULO 600mg + LDAC - Ph1	ULO 800mg + LDAC - Ph1		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3	3		
Units: Participants				
ABSOLUTE NEUTROPHIL COUNT - grade 3	0	1		
ABSOLUTE NEUTROPHIL COUNT - grade 4	3	2		
ALANINE AMINOTRANSFERASE - grade 0	2	2		
ALANINE AMINOTRANSFERASE - grade 1	1	1		
ALBUMIN - grade 0	1	0		
ALBUMIN - grade 1	0	2		
ALBUMIN - grade 2	2	1		
ALKALINE PHOSPHATASE - grade 0	2	2		
ALKALINE PHOSPHATASE grade 1	1	1		
ASPARTATE AMINOTRANSFERASE - grade 0	3	2		
ASPARTATE AMINOTRANSFERASE - grade 1	0	1		
BILIRUBIN, TOTAL - grade 0	3	2		
BILIRUBIN, TOTAL - grade 2	0	1		
CALCIUM, TOTAL - grade 0	1	1		

CALCIUM, TOTAL - grade 1	0	1		
CALCIUM, TOTAL - grade 2	2	1		
CREATINE KINASE - grade 0	3	3		
CREATININE - grade 0	2	3		
CREATININE - grade 1	1	0		
FIBRINOGEN - grade 0	1	0		
GLUCOSE, FASTING SERUM - grade 0	1	1		
GLUCOSE, FASTING SERUM - grade 1	2	0		
GLUCOSE, FASTING SERUM - grade 2	0	2		
HEMOGLOBIN - grade 2	1	1		
HEMOGLOBIN - grade 3	2	2		
LEUKOCYTES - grade 0	0	1		
LEUKOCYTES - grade 3	1	1		
LEUKOCYTES - grade 4	2	1		
LIPASE, TOTAL (COLORIMETRIC ASSAY) - grade 0	2	1		
LIPASE, TOTAL (COLORIMETRIC ASSAY) - grade 1	1	0		
LIPASE, TOTAL (COLORIMETRIC ASSAY) - grade 3	0	2		
LYMPHOCYTES (ABSOLUTE) - grade 0	0	1		
LYMPHOCYTES (ABSOLUTE) - grade 1	0	1		
LYMPHOCYTES (ABSOLUTE) - grade 2	2	1		
LYMPHOCYTES (ABSOLUTE) - grade 3	1	0		
NEUTROPHILS (ABSOLUTE) - grade 3	0	1		
NEUTROPHILS (ABSOLUTE) - grade 4	3	2		
PHOSPHORUS, INORGANIC - grade 0	3	2		
PHOSPHORUS, INORGANIC - grade 3	0	1		
PLATELET COUNT - grade 3	0	1		
PLATELET COUNT - grade 4	3	2		
POTASSIUM, SERUM - grade 0	1	2		
POTASSIUM, SERUM - grade 1	0	1		
POTASSIUM, SERUM - grade 3	2	0		
SODIUM, SERUM - grade 0	2	1		
SODIUM, SERUM - grade 1	0	2		
SODIUM, SERUM - grade 3	1	0		
URIC ACID - grade 0	3	2		
URIC ACID - grade 1	0	1		

Statistical analyses

No statistical analyses for this end point

Primary: Best Overall Response (BOR) - Phase 2

End point title	Best Overall Response (BOR) - Phase 2[15][16]

End point description:

The phase 2 primary endpoint was based on the rate of Complete Remission (CR/CRi) prior to the initiation of any alternative therapy (including any subsequent ulocuplumab 800 mg for participants in the LDAC alone arm). The phase 2 primary analysis was conducted after all participants had an opportunity for 6 months of follow-up. Complete remission rate: CR + CRi, confidence interval based on the Clopper and Pearson method. CR = complete response CRi = complete response, incomplete blood

count

End point type	Primary

End point timeframe:

From first dose until a minimum follow-up of up to 2 months

Notes:

[15] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: Only summary statistics were planned for this endpoint

[16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Only phase 2 summary statistics were planned for this endpoint

End point values	ULO 800mg + LDAC - Ph2	ULO 1000mg + LDAC - Ph2	LDAC - Ph2	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	26	14	24	
Units: Percentage of participants				
number (confidence interval 95%)	15.4 (4.4 to 34.9)	7.1 (0.2 to 33.9)	25.0 (9.8 to 46.7)	

Statistical analyses

No statistical analyses for this end point

Secondary: Best Overall Response (BOR) - Phase 1

End point title	Best Overall Response (BOR) - Phase 1[17]

End point description:

Investigator assessed best overall response prior to the initiation of any alternative therapy for Phase 1 participants.

End point type	Secondary

End point timeframe:

From first dose until a minimum follow-up of up to 2 months

Notes:

[17] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Only phase 1 summary statistics were planned for this endpoint

End point values	ULO 600mg + LDAC - Ph1	ULO 800mg + LDAC - Ph1		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3	3		
Units: Participants	1	3		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with AEs - Phase 2

End point title	Number of participants with AEs - Phase 2[18]

End point description:

The number of participants with an on-study adverse event (AE). Safety data are evaluated for AEs, defined and evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 (NCI CTCAE v4.03).

End point type	Secondary

End point timeframe:

From first dose until a minimum follow-up of up to 2 months

Notes:

[18] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Only phase 2 summary statistics were planned for this endpoint

End point values	ULO 800mg + LDAC - Ph2	ULO 1000mg + LDAC - Ph2	LDAC - Ph2	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	26	14	22	
Units: Participants	25	14	22	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with AEs leading to discontinuation - Phase 2

End point title	Number of participants with AEs leading to discontinuation - Phase 2[19]

End point description:

The number of participants with an on-study adverse event (AE) leading to discontinuation. Safety data are evaluated for AEs leading to discontinuation, defined and evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 (NCI CTCAE v4.03).

End point type	Secondary

End point timeframe:

From first dose until a minimum follow-up of up to 2 months

Notes:

[19] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Only phase 2 summary statistics were planned for this endpoint

End point values	ULO 800mg + LDAC - Ph2	ULO 1000mg + LDAC - Ph2	LDAC - Ph2	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	26	14	22	
Units: Participants	7	3	4	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with SAEs - Phase 2

End point title	Number of participants with SAEs - Phase 2[20]

End point description:

The number of participants with an on-study serious adverse event (SAE). Safety data are evaluated for SAEs, defined and evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 (NCI CTCAE v4.03).

End point type	Secondary

End point timeframe:

From first dose until a minimum follow-up of up to 2 months

Notes:

[20] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Only phase 2 summary statistics were planned for this endpoint

End point values	ULO 800mg + LDAC - Ph2	ULO 1000mg + LDAC - Ph2	LDAC - Ph2	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	26	14	22	
Units: Participants	21	8	15	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of deaths- Phase 2

End point title	Number of deaths- Phase 2[21]

End point description:

The number of participants who died. Safety data are evaluated for deaths, defined and evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 (NCI CTCAE v4.03).

End point type	Secondary

End point timeframe:

From first dose until a minimum follow-up of up to 2 months

Notes:

[21] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Only phase 2 summary statistics were planned for this endpoint

End point values	ULO 800mg + LDAC - Ph2	ULO 1000mg + LDAC - Ph2	LDAC - Ph2	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	26	14	22	
Units: Participants	19	10	16	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with laboratory abnormalities - Phase 2

End point title	Number of participants with laboratory abnormalities - Phase

End point description:

The number of participants with an on-study laboratory abnormality. Safety data are evaluated for laboratory abnormalities, defined and evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 (NCI CTCAE v4.03).

End point type	Secondary

End point timeframe:

From first dose until a minimum follow-up of up to 2 months

Notes:

[22] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Only phase 2 summary statistics were planned for this endpoint

End point values	ULO 800mg + LDAC - Ph2	ULO 1000mg + LDAC - Ph2	LDAC - Ph2	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	26	14	22	
Units: Participants	9999	9999	9999	

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with anti-drug antibodies (ADA) positive for ulocuplumab - Phases 1 and 2

End point title	Number of participants with anti-drug antibodies (ADA) positive for ulocuplumab - Phases 1 and 2[23]

End point description:

Serum samples from ulocuplumab treated participants were evaluated for the presence of anti-ulocuplumab antibodies

End point type	Secondary

End point timeframe:

From first dose until a minimum follow-up of up to 2 months

Notes:

[23] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Only drug summary statistics were planned for this endpoint

End point values	ULO 600mg + LDAC - Ph1	ULO 800mg + LDAC - Ph1	ULO 800mg + LDAC - Ph2	ULO 1000mg + LDAC - Ph2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	21	14
Units: Participants	9999	9999	6	0

Statistical analyses

No statistical analyses for this end point

Secondary: Maximum observed serum concentration (Cmax) - Phases 1 and 2

End point title	Maximum observed serum concentration (Cmax) - Phases 1 and 2

End point description:

The Pharmacokinetic (PK) parameters are assessed for ulocuplumab following study drug administration EOT = end of treatment

End point type	Secondary

End point timeframe:

Days 1, 8, 15 for cycles 1 and 2; Days 1, 8 for cycles 3-5; Day 1 every 4th cycle thereafter; EOT; 30 days post last dose (follow-up)

End point values	ULO 600mg + LDAC - Ph1	ULO 800mg + LDAC - Ph1	ULO 800mg + LDAC - Ph2	ULO 1000mg + LDAC - Ph2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	26	14
Units: ng/mL				
geometric mean (geometric coefficient of variation)	9999 (± 9999)	9999 (± 9999)	9999 (± 9999)	9999 (± 9999)

End point values	LDAC - Ph2			
Subject group type	Reporting group			
Number of subjects analysed	22			
Units: ng/mL				
geometric mean (geometric coefficient of variation)	9999 (± 9999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Trough observed serum concentration (Ctrough) - Phases 1 and 2

End point title	Trough observed serum concentration (Ctrough) - Phases 1 and 2

End point description:

The Pharmacokinetic (PK) parameters are assessed for ulocuplumab following study drug administration. EOT = end of treatment

End point type	Secondary

End point timeframe:

Days 1, 8, 15 for cycles 1 and 2; Days 1, 8 for cycles 3-5; Day 1 every 4th cycle thereafter; EOT; 30 days post last dose (follow-up)

End point values	ULO 600mg + LDAC - Ph1	ULO 800mg + LDAC - Ph1	ULO 800mg + LDAC - Ph2	ULO 1000mg + LDAC - Ph2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	26	14
Units: ng/mL				
geometric mean (geometric coefficient of variation)	9999 (± 9999)	9999 (± 9999)	9999 (± 9999)	9999 (± 9999)

End point values	LDAC - Ph2			
Subject group type	Reporting group			
Number of subjects analysed	22			
Units: ng/mL				
geometric mean (geometric coefficient of variation)	9999 (± 9999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Time of maximum observed ulocuplumab serum concentration (Tmax) - Phases 1 and 2

End point title	Time of maximum observed ulocuplumab serum concentration (Tmax) - Phases 1 and 2

End point description:

The Pharmacokinetic (PK) parameters are assessed for ulocuplumab following study drug administration. EOT = end of treatment

End point type	Secondary

End point timeframe:

Days 1, 8, 15 for cycles 1 and 2; Days 1, 8 for cycles 3-5; Day 1 every 4th cycle thereafter; EOT; 30 days post last dose (follow-up)

End point values	ULO 600mg + LDAC - Ph1	ULO 800mg + LDAC - Ph1	ULO 800mg + LDAC - Ph2	ULO 1000mg + LDAC - Ph2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	26	14
Units: hour (H)				
median (full range (min-max))	9999 (-9999 to 9999)	9999 (-9999 to 9999)	9999 (-9999 to 9999)	9999 (-9999 to 9999)

End point values	LDAC - Ph2			
Subject group type	Reporting group			
Number of subjects analysed	22			
Units: hour (H)				

median (full range (min-max))	9999 (-9999 to 9999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Area under the ulocuplumab concentration-time curve from time zero to the last quantifiable concentration [AUC(0-T)] - Phases 1 and 2

End point title	Area under the ulocuplumab concentration-time curve from time zero to the last quantifiable concentration [AUC(0-T)] - Phases 1 and 2

End point description:

The Pharmacokinetic (PK) parameters are assessed for ulocuplumab following study drug administration. EOT = end of treatment AUC(0-T) calculated by log- and linear-trapezoidal summation

End point type	Secondary

End point timeframe:

Days 1, 8, 15 for cycles 1 and 2; Days 1, 8 for cycles 3-5; Day 1 every 4th cycle thereafter; EOT; 30 days post last dose (follow-up)

End point values	ULO 600mg + LDAC - Ph1	ULO 800mg + LDAC - Ph1	ULO 800mg + LDAC - Ph2	ULO 1000mg + LDAC - Ph2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	26	14
Units: ng.h/mL				
geometric mean (geometric coefficient of variation)	9999 (± 9999)	9999 (± 9999)	9999 (± 9999)	9999 (± 9999)

End point values	LDAC - Ph2			
Subject group type	Reporting group			
Number of subjects analysed	22			
Units: ng.h/mL				
geometric mean (geometric coefficient of variation)	9999 (± 9999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Area under the ulocuplumab concentration-time curve in one dosing interval [AUC(TAU)] - Phases 1 and 2

End point title	Area under the ulocuplumab concentration-time curve in one dosing interval [AUC(TAU)] - Phases 1 and 2

End point description:

The Pharmacokinetic (PK) parameters are assessed for ulocuplumab following study drug administration. EOT = end of treatment

End point type	Secondary

End point timeframe:

Days 1, 8, 15 for cycles 1 and 2; Days 1, 8 for cycles 3-5; Day 1 every 4th cycle thereafter; EOT; 30 days post last dose (follow-up)

End point values	ULO 600mg + LDAC - Ph1	ULO 800mg + LDAC - Ph1	ULO 800mg + LDAC - Ph2	ULO 1000mg + LDAC - Ph2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	26	14
Units: ng.h/mL				
geometric mean (geometric coefficient of variation)	9999 (± 9999)	9999 (± 9999)	9999 (± 9999)	9999 (± 9999)

End point values	LDAC - Ph2			
Subject group type	Reporting group			
Number of subjects analysed	22			
Units: ng.h/mL				
geometric mean (geometric coefficient of variation)	9999 (± 9999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Area under the ulocuplumab concentration-time curve from time zero to infinity [AUC(INF)] - Phases 1 and 2

End point title	Area under the ulocuplumab concentration-time curve from time zero to infinity [AUC(INF)] - Phases 1 and 2

End point description:

The Pharmacokinetic (PK) parameters are assessed for ulocuplumab following study drug administration. EOT = end of treatment AUC(INF) calculated by summing AUC(0-T) and the extrapolated area, computed by the quotient Clast/λz

End point type	Secondary

End point timeframe:

Days 1, 8, 15 for cycles 1 and 2; Days 1, 8 for cycles 3-5; Day 1 every 4th cycle thereafter; EOT; 30 days post last dose (follow-up)

End point values	ULO 600mg + LDAC - Ph1	ULO 800mg + LDAC - Ph1	ULO 800mg + LDAC - Ph2	ULO 1000mg + LDAC - Ph2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	26	14
Units: ng.h/mL				
geometric mean (geometric coefficient of variation)	9999 (± 9999)	9999 (± 9999)	9999 (± 9999)	9999 (± 9999)

End point values	LDAC - Ph2			
Subject group type	Reporting group			
Number of subjects analysed	22			
Units: ng.h/mL				
geometric mean (geometric coefficient of variation)	9999 (± 9999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Elimination half-life (T-HALF) - Phases 1 and 2

End point title	Elimination half-life (T-HALF) - Phases 1 and 2

End point description:

The Pharmacokinetic (PK) parameters are assessed for ulocuplumab following study drug administration. EOT = end of treatment T-HALF determined as 0.693/λz

End point type	Secondary

End point timeframe:

Days 1, 8, 15 for cycles 1 and 2; Days 1, 8 for cycles 3-5; Day 1 every 4th cycle thereafter; EOT; 30 days post last dose (follow-up)

End point values	ULO 600mg + LDAC - Ph1	ULO 800mg + LDAC - Ph1	ULO 800mg + LDAC - Ph2	ULO 1000mg + LDAC - Ph2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	26	14
Units: hour (H)				
arithmetic mean (standard deviation)	9999 (± 9999)	9999 (± 9999)	9999 (± 9999)	9999 (± 9999)

End point values	LDAC - Ph2			
Subject group type	Reporting group			
Number of subjects analysed	22			
Units: hour (H)				
arithmetic mean (standard deviation)	9999 (± 9999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Total body clearance of ulocuplumab (CLT) - Phases 1 and 2

End point title	Total body clearance of ulocuplumab (CLT) - Phases 1 and 2

End point description:

The Pharmacokinetic (PK) parameters are assessed for ulocuplumab following study drug administration. EOT = end of treatment CLT calculated by dividing the total dose of ulocuplumab by its corresponding AUC(INF) value

End point type	Secondary

End point timeframe:

Days 1, 8, 15 for cycles 1 and 2; Days 1, 8 for cycles 3-5; Day 1 every 4th cycle thereafter; EOT; 30 days post last dose (follow-up)

End point values	ULO 600mg + LDAC - Ph1	ULO 800mg + LDAC - Ph1	ULO 800mg + LDAC - Ph2	ULO 1000mg + LDAC - Ph2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	26	14
Units: mL/h				
geometric mean (geometric coefficient of variation)	9999 (± 9999)	9999 (± 9999)	9999 (± 9999)	9999 (± 9999)

End point values	LDAC - Ph2			
Subject group type	Reporting group			
Number of subjects analysed	22			
Units: mL/h				
geometric mean (geometric coefficient of variation)	9999 (± 9999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Volume of distribution at steady state (Vss) - Phases 1 and 2

End point title	Volume of distribution at steady state (Vss) - Phases 1 and 2

End point description:

The Pharmacokinetic (PK) parameters are assessed for ulocuplumab following study drug administration. EOT = end of treatment

End point type	Secondary

End point timeframe:

Days 1, 8, 15 for cycles 1 and 2; Days 1, 8 for cycles 3-5; Day 1 every 4th cycle thereafter; EOT; 30 days post last dose (follow-up)

End point values	ULO 600mg + LDAC - Ph1	ULO 800mg + LDAC - Ph1	ULO 800mg + LDAC - Ph2	ULO 1000mg + LDAC - Ph2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	26	14
Units: liter (L)				
geometric mean (geometric coefficient of variation)	9999 (± 9999)	9999 (± 9999)	9999 (± 9999)	9999 (± 9999)

End point values	LDAC - Ph2			
Subject group type	Reporting group			
Number of subjects analysed	22			
Units: liter (L)				
geometric mean (geometric coefficient of variation)	9999 (± 9999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Overall rate of remission in participants treated with ulocuplumab at two different dose levels 800 mg and 1000 mg in combination with LDAC - Phase 2

End point title	Overall rate of remission in participants treated with ulocuplumab at two different dose levels 800 mg and 1000 mg in combination with LDAC - Phase 2[24]

End point description:

This phase 2 secondary endpoint was based on the rate of Overall Remission (OR=PR+CR +CRi) prior to the initiation of any alternative therapy (including any subsequent ulocuplumab 800 mg for participants in the LDAC alone arm). The phase 2 analysis was conducted after all participants had an opportunity for 6 months of follow-up. Overall remission rate: CR + CRi, + PR confidence interval based on the Clopper and Pearson method. CR = complete response CRi = complete response, incomplete blood count PR = partial remission

End point type	Secondary

End point timeframe:

From first dose until a minimum follow-up of up to 2 months

Notes:

[24] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Only phase 2 summary statistics were planned for this endpoint

End point values	ULO 800mg + LDAC - Ph2	ULO 1000mg + LDAC - Ph2		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	26	14		
Units: Percentage of participants				
number (confidence interval 95%)	19.2 (6.6 to 39.4)	7.1 (0.2 to 33.9)		

Statistical analyses

No statistical analyses for this end point

Secondary: Duration of response in participants with CR/CRi treated with ulocuplumab at two different dose levels 800 mg and 1000 mg in combination with LDAC - Phase 2

End point title	Duration of response in participants with CR/CRi treated with ulocuplumab at two different dose levels 800 mg and 1000 mg in combination with LDAC - Phase 2[25]

End point description:

This phase 2 secondary endpoint was based on the duration of complete remission prior to the initiation of any alternative therapy (including any subsequent ulocuplumab 800 mg for participants in the LDAC alone arm). The phase 2 analysis was conducted after all participants had an opportunity for 6 months of follow-up.

End point type	Secondary

End point timeframe:

From first dose until a minimum follow-up of up to 2 months

Notes:

[25] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Only phase 2 summary statistics were planned for this endpoint

End point values	ULO 800mg + LDAC - Ph2	ULO 1000mg + LDAC - Ph2		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	4	1		
Units: Months				
median (full range (min-max))	2.4 (0.5 to 5.6)	4.3 (-9999 to 9999)		

Statistical analyses

No statistical analyses for this end point

Secondary: Rate of Complete Remission (CR/CRi) and Overall rate of remission in participants treated with LDAC only - Phase 2

End point title	Rate of Complete Remission (CR/CRi) and Overall rate of remission in participants treated with LDAC only - Phase 2[26]

End point description:

This phase 2 secondary endpoint was based on the rate of Complete Remission (CR/CRi) and rate of Overall Remission (OR=PR+CR +CRi) prior to the initiation of any alternative therapy (including any

subsequent ulocuplumab 800 mg for participants in the LDAC alone arm). The phase 2 analysis was conducted after all participants had an opportunity for 6 months of follow-up. Overall remission rate: CR + CRi, + PR confidence interval based on the Clopper and Pearson method. CR = complete response CRi = complete response, incomplete blood count PR = partial remission

End point type	Secondary

End point timeframe:

From first dose until a minimum follow-up of up to 2 months

Notes:

[26] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Only phase 2 summary statistics were planned for this endpoint

End point values	LDAC - Ph2			
Subject group type	Reporting group			
Number of subjects analysed	24			
Units: Percentage of participants				
number (confidence interval 95%)				
CR/CRi	25.0 (9.8 to 46.7)			
Overall remission rate	25.0 (9.8 to 46.7)			

Statistical analyses

No statistical analyses for this end point

Secondary: Duration of response in participants with CR/CRi treated with LDAC only - Phase 2

End point title	Duration of response in participants with CR/CRi treated with LDAC only - Phase 2[27]

End point description:

This phase 2 secondary endpoint was based on the duration of complete remission prior to the initiation of any alternative therapy (including any subsequent ulocuplumab 800 mg for participants in the LDAC alone arm). The phase 2 analysis was conducted after all participants had an opportunity for 6 months of follow-up.

End point type	Secondary

End point timeframe:

From first dose until a minimum follow-up of up to 2 months

Notes:

[27] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Only phase 2 summary statistics were planned for this endpoint

End point values	LDAC - Ph2			
Subject group type	Reporting group			
Number of subjects analysed	6			
Units: Months				
median (full range (min-max))	5.7 (0.9 to 9999)			

Statistical analyses

No statistical analyses for this end point

Secondary: Change in baseline of electrocardiogram (ECG) endpoints - Phases 1 and 2

End point title	Change in baseline of electrocardiogram (ECG) endpoints - Phases 1 and 2

End point description:

Change in baseline of ECG endpoints:

End point type	Secondary

End point timeframe:

From first dose until a minimum follow-up of up to 2 months

End point values	ULO 600mg + LDAC - Ph1	ULO 800mg + LDAC - Ph1	ULO 800mg + LDAC - Ph2	ULO 1000mg + LDAC - Ph2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	26	14
Units: Percent change from baseline	9999	9999	9999	9999

End point values	LDAC - Ph2			
Subject group type	Reporting group			
Number of subjects analysed	24			
Units: Percent change from baseline	9999			

Statistical analyses

No statistical analyses for this end point

Secondary: Overall survival (OS) - Phases 1 and 2

End point title	Overall survival (OS) - Phases 1 and 2

End point description:

OS is defined as the time between the first date of treatment and the date of death due to any cause. A participant who has not died was be censored at the last known alive date.

End point type	Secondary

End point timeframe:

From first dose until a minimum follow-up of up to 2 months

End point values	ULO 600mg + LDAC - Ph1	ULO 800mg + LDAC - Ph1	ULO 800mg + LDAC - Ph2	ULO 1000mg + LDAC - Ph2
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	3	26	14
Units: Months				
median (full range (min-max))	9999 (-9999 to 9999)	9999 (-9999 to 9999)	3.3 (1.8 to 8.7)	3.0 (1.8 to 4.7)

End point values	LDAC - Ph2			
Subject group type	Reporting group			
Number of subjects analysed	22			
Units: Months				
median (full range (min-max))	6.9 (1.6 to 12.7)			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Adverse events are reported from start of treatment up to 30 days after last dose of study treatment.

Adverse event reporting additional description:

Analysis was performed in All treated subjects defined as all subjects who received at least one dose of any study medication.

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	22.0

Reporting groups

Reporting group title	Dose escalation: Ulocuplumab 600 mg + LDAC

Reporting group description:

During escalation phase subjects were administered intravenously (IV) with 600 mg ulocuplumab on Days 1, 8, and 15 in combination with low dose cytarabine (LDAC) (20 milligram (mg) twice daily (BID) [40 mg/day], administered subcutaneously [SC]) on Days 1 through 10 of each 28-day cycle (Cycles 1 and 2). For Cycle 3 and subsequent cycles subjects received ulocuplumab 600 mg on Days 1 and 8 in combination with LDAC (20 mg BID, SC) on Days 1 through 10.

Reporting group title	Dose escalation: Ulocuplumab 800 mg + LDAC

Reporting group description:

During escalation phase subjects were administered IV with 800 mg ulocuplumab on Days 1, 8, and 15 in combination with LDAC (20 mg BID [40 mg/day], administered SC) on Days 1 through 10 of each 28-day cycle (Cycles 1 and 2). For Cycle 3 and subsequent cycles subjects received ulocuplumab 800 mg on Days 1 and 8 in combination with LDAC (20 mg BID, SC) on Days 1 through 10.

Reporting group title	Dose expansion: Ulocuplumab 800mg + LDAC

Reporting group description:

During expansion phase subjects were administered IV with 800 mg ulocuplumab on Days 1, 8, and 15 in combination with LDAC (20 mg BID [40 mg/day], administered SC) on Days 1 through 10 of each 28-day cycle (Cycles 1 and 2). For Cycle 3 and subsequent cycles subjects received ulocuplumab 800 mg on Days 1 and 8 in combination with LDAC (20 mg BID, SC) on Days 1 through 10.

Reporting group title	Dose expansion: Ulocuplumab 1000mg + LDAC

Reporting group description:

During expansion phase subjects were administered IV with 1000 mg ulocuplumab on Days 1, 8, and 15 in combination with LDAC (20 mg BID [40 mg/day], administered SC) on Days 1 through 10 of each 28-day cycle (Cycles 1 and 2). For Cycle 3 and subsequent cycles subjects received ulocuplumab 1000 mg on Days 1 and 8 in combination with LDAC (20 mg BID, SC) on Days 1 through 10.

Reporting group title	Dose expansion: LDAC alone

Reporting group description:

During expansion phase subjects were administered SC with LDAC (20 mg BID [40 mg/day]) on Days 1 through 10 for cycle 1 and subsequent cycles (28-day cycle).

Serious adverse events	Dose escalation: Ulocuplumab 600 mg + LDAC	Dose escalation: Ulocuplumab 800 mg + LDAC	Dose expansion: Ulocuplumab 800mg + LDAC
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 3 (66.67%)	1 / 3 (33.33%)	21 / 26 (80.77%)
number of deaths (all causes)	0	0	19
number of deaths resulting from adverse events			

Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Acute myeloid leukaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epstein-Barr virus associated lymphoproliferative disorder			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malignant neoplasm progression			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	5 / 26 (19.23%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 5
Vascular disorders			
Circulatory collapse			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 26 (3.85%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Deep vein thrombosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 26 (3.85%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Hypotension			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neurogenic shock			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Catheter site haemorrhage			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 26 (3.85%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Complication associated with device			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 26 (3.85%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Death			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 26 (3.85%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epistaxis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 26 (3.85%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 26 (3.85%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Pulmonary haemorrhage			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 26 (3.85%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary oedema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 26 (3.85%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	2 / 26 (7.69%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Psychiatric disorders			
Confusional state			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 26 (3.85%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Amylase increased			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Wound dehiscence			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 26 (3.85%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Arrhythmia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 26 (3.85%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorder			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebrovascular accident			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 26 (3.85%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dizziness			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Disseminated intravascular coagulation			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Febrile neutropenia			
subjects affected / exposed	2 / 3 (66.67%)	0 / 3 (0.00%)	8 / 26 (30.77%)
occurrences causally related to treatment / all	2 / 2	0 / 0	7 / 12
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Eye disorders			
Cataract			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Colitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 26 (3.85%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	2 / 26 (7.69%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	2 / 26 (7.69%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Intestinal obstruction			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 26 (3.85%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophagitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 26 (3.85%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Vomiting			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Bacterial infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile colitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 26 (3.85%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	2 / 26 (7.69%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophageal candidiasis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 26 (3.85%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	3 / 26 (11.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia fungal			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 26 (3.85%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	3 / 26 (11.54%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Septic shock			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 26 (3.85%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Sinusitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 26 (3.85%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypokalaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 26 (3.85%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lactic acidosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 26 (3.85%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tumour lysis syndrome			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 26 (3.85%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Dose expansion: Ulocuplumab 1000mg + LDAC	Dose expansion: LDAC alone	
Total subjects affected by serious adverse events			
subjects affected / exposed	8 / 14 (57.14%)	15 / 22 (68.18%)	
number of deaths (all causes)	10	16	
number of deaths resulting from			

adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Acute myeloid leukaemia			
subjects affected / exposed	1 / 14 (7.14%)	0 / 22 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Epstein-Barr virus associated lymphoproliferative disorder			
subjects affected / exposed	0 / 14 (0.00%)	0 / 22 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Malignant neoplasm progression			
subjects affected / exposed	2 / 14 (14.29%)	6 / 22 (27.27%)	
occurrences causally related to treatment / all	0 / 2	0 / 6	
deaths causally related to treatment / all	0 / 2	0 / 6	
Vascular disorders			
Circulatory collapse			
subjects affected / exposed	0 / 14 (0.00%)	0 / 22 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Deep vein thrombosis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 22 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypotension			
subjects affected / exposed	0 / 14 (0.00%)	1 / 22 (4.55%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neurogenic shock			
subjects affected / exposed	0 / 14 (0.00%)	1 / 22 (4.55%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Catheter site haemorrhage			

subjects affected / exposed	0 / 14 (0.00%)	0 / 22 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Complication associated with device			
subjects affected / exposed	0 / 14 (0.00%)	0 / 22 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Death			
subjects affected / exposed	1 / 14 (7.14%)	0 / 22 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Fatigue			
subjects affected / exposed	0 / 14 (0.00%)	1 / 22 (4.55%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pyrexia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 22 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Dyspnoea			
subjects affected / exposed	0 / 14 (0.00%)	1 / 22 (4.55%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Epistaxis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 22 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary embolism			
subjects affected / exposed	0 / 14 (0.00%)	0 / 22 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary haemorrhage			

subjects affected / exposed	0 / 14 (0.00%)	0 / 22 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary oedema			
subjects affected / exposed	1 / 14 (7.14%)	1 / 22 (4.55%)	
occurrences causally related to treatment / all	0 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory failure			
subjects affected / exposed	1 / 14 (7.14%)	0 / 22 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Confusional state			
subjects affected / exposed	0 / 14 (0.00%)	0 / 22 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Investigations			
Amylase increased			
subjects affected / exposed	0 / 14 (0.00%)	0 / 22 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Wound dehiscence			
subjects affected / exposed	0 / 14 (0.00%)	0 / 22 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Arrhythmia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 22 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorder			

subjects affected / exposed	1 / 14 (7.14%)	0 / 22 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Cardiac failure			
subjects affected / exposed	0 / 14 (0.00%)	0 / 22 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Cerebrovascular accident			
subjects affected / exposed	0 / 14 (0.00%)	0 / 22 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dizziness			
subjects affected / exposed	0 / 14 (0.00%)	1 / 22 (4.55%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Seizure			
subjects affected / exposed	0 / 14 (0.00%)	1 / 22 (4.55%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Syncope			
subjects affected / exposed	0 / 14 (0.00%)	1 / 22 (4.55%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 14 (0.00%)	1 / 22 (4.55%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Disseminated intravascular coagulation			
subjects affected / exposed	0 / 14 (0.00%)	0 / 22 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Febrile neutropenia			
subjects affected / exposed	5 / 14 (35.71%)	6 / 22 (27.27%)	
occurrences causally related to treatment / all	1 / 7	5 / 7	
deaths causally related to treatment / all	0 / 0	0 / 1	
Eye disorders			
Cataract			
subjects affected / exposed	0 / 14 (0.00%)	0 / 22 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Colitis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 22 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea			
subjects affected / exposed	0 / 14 (0.00%)	2 / 22 (9.09%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 14 (0.00%)	0 / 22 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal obstruction			
subjects affected / exposed	0 / 14 (0.00%)	1 / 22 (4.55%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nausea			
subjects affected / exposed	0 / 14 (0.00%)	0 / 22 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophagitis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 22 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Vomiting			
subjects affected / exposed	0 / 14 (0.00%)	1 / 22 (4.55%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Bacterial infection			
subjects affected / exposed	0 / 14 (0.00%)	1 / 22 (4.55%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Clostridium difficile colitis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 22 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung infection			
subjects affected / exposed	0 / 14 (0.00%)	0 / 22 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophageal candidiasis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 22 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	0 / 14 (0.00%)	1 / 22 (4.55%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pneumonia fungal			
subjects affected / exposed	0 / 14 (0.00%)	0 / 22 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis			
subjects affected / exposed	2 / 14 (14.29%)	1 / 22 (4.55%)	
occurrences causally related to treatment / all	1 / 3	0 / 1	
deaths causally related to treatment / all	0 / 2	0 / 1	
Septic shock			

subjects affected / exposed	0 / 14 (0.00%)	1 / 22 (4.55%)	
occurrences causally related to treatment / all	0 / 0	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Sinusitis			
subjects affected / exposed	1 / 14 (7.14%)	0 / 22 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin infection			
subjects affected / exposed	0 / 14 (0.00%)	1 / 22 (4.55%)	
occurrences causally related to treatment / all	0 / 0	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 14 (0.00%)	1 / 22 (4.55%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypokalaemia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 22 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lactic acidosis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 22 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Tumour lysis syndrome			
subjects affected / exposed	1 / 14 (7.14%)	1 / 22 (4.55%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Dose escalation: Ulocuplumab 600 mg + LDAC	Dose escalation: Ulocuplumab 800 mg + LDAC	Dose expansion: Ulocuplumab 800mg + LDAC
Total subjects affected by non-serious adverse events			
subjects affected / exposed	3 / 3 (100.00%)	3 / 3 (100.00%)	23 / 26 (88.46%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Acute myeloid leukaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 26 (3.85%)
occurrences (all)	0	0	1
Vascular disorders			
Haematoma			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	2 / 26 (7.69%)
occurrences (all)	0	0	2
Haemorrhage			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Hypertension			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	3 / 26 (11.54%)
occurrences (all)	1	0	3
Hypotension			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Vasculitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	3 / 26 (11.54%)
occurrences (all)	0	0	4
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	3 / 26 (11.54%)
occurrences (all)	0	0	3
Catheter site erythema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	2 / 26 (7.69%)
occurrences (all)	0	0	2
Chills			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 26 (3.85%)
occurrences (all)	0	0	1
Early satiety			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Fatigue			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	5 / 26 (19.23%)
occurrences (all)	0	0	5
Generalised oedema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 26 (3.85%)
occurrences (all)	0	0	1
Malaise			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	3 / 26 (11.54%)
occurrences (all)	0	0	3
Mass			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Mucosal inflammation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Oedema peripheral			
subjects affected / exposed	1 / 3 (33.33%)	2 / 3 (66.67%)	6 / 26 (23.08%)
occurrences (all)	4	2	6
Pyrexia			
subjects affected / exposed	2 / 3 (66.67%)	2 / 3 (66.67%)	8 / 26 (30.77%)
occurrences (all)	4	4	9
Non-Cardiac chest pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	2 / 26 (7.69%)
occurrences (all)	0	0	2
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	1 / 3 (33.33%)	1 / 3 (33.33%)	1 / 26 (3.85%)
occurrences (all)	1	1	1
Reproductive system and breast disorders			
Breast pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Genital ulceration			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Prostatitis			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 26 (0.00%)
occurrences (all)	0	1	0
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	0 / 3 (0.00%)	2 / 3 (66.67%)	6 / 26 (23.08%)
occurrences (all)	0	2	6
Dyspnoea			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	5 / 26 (19.23%)
occurrences (all)	0	0	6
Dyspnoea exertional			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Epistaxis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	2 / 26 (7.69%)
occurrences (all)	0	0	3
Hypoxia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 26 (3.85%)
occurrences (all)	0	0	1
Interstitial lung disease			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	3 / 26 (11.54%)
occurrences (all)	0	1	3
Pleural effusion			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 26 (3.85%)
occurrences (all)	0	0	1
Productive cough			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	3 / 26 (11.54%)
occurrences (all)	0	0	3
Rhinorrhoea			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Stridor			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract inflammation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Wheezing			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Adjustment disorder with depressed mood			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Anxiety			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Confusional state			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	2 / 26 (7.69%)
occurrences (all)	0	0	2
Delirium			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Insomnia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	7 / 26 (26.92%)
occurrences (all)	0	0	9
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	2 / 26 (7.69%)
occurrences (all)	1	0	2
Amylase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	2 / 26 (7.69%)
occurrences (all)	0	0	2
Aspartate aminotransferase increased			

subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	1 / 26 (3.85%)
occurrences (all)	1	0	1
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	1 / 26 (3.85%)
occurrences (all)	0	1	1
Blood bilirubin increased			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	3 / 26 (11.54%)
occurrences (all)	0	1	3
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Blood creatinine increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 26 (3.85%)
occurrences (all)	0	0	1
Lipase increased			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	2 / 26 (7.69%)
occurrences (all)	5	0	2
Neutrophil count decreased			
subjects affected / exposed	2 / 3 (66.67%)	0 / 3 (0.00%)	3 / 26 (11.54%)
occurrences (all)	5	0	4
Platelet count decreased			
subjects affected / exposed	2 / 3 (66.67%)	3 / 3 (100.00%)	6 / 26 (23.08%)
occurrences (all)	17	5	7
Weight decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
White blood cell count decreased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	5 / 26 (19.23%)
occurrences (all)	0	0	5
C-Reactive protein increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Electrocardiogram qt prolonged			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 26 (3.85%)
occurrences (all)	0	0	1

Troponin t increased			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Allergic transfusion reaction			
subjects affected / exposed	1 / 3 (33.33%)	1 / 3 (33.33%)	0 / 26 (0.00%)
occurrences (all)	1	2	0
Compression fracture			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Fall			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 26 (3.85%)
occurrences (all)	0	0	1
Infusion related reaction			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Procedural pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 26 (3.85%)
occurrences (all)	0	0	1
Transfusion reaction			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	2 / 26 (7.69%)
occurrences (all)	1	0	2
Cardiac failure			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Tachycardia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	2 / 26 (7.69%)
occurrences (all)	0	0	2
Nervous system disorders			
Dizziness			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	2 / 26 (7.69%)
occurrences (all)	0	0	2

Headache			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	3 / 26 (11.54%)
occurrences (all)	0	0	3
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	2 / 3 (66.67%)	3 / 3 (100.00%)	11 / 26 (42.31%)
occurrences (all)	3	4	22
Febrile neutropenia			
subjects affected / exposed	1 / 3 (33.33%)	3 / 3 (100.00%)	5 / 26 (19.23%)
occurrences (all)	1	3	7
Increased tendency to bruise			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Leukocytosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 26 (3.85%)
occurrences (all)	0	0	1
Neutropenia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	4 / 26 (15.38%)
occurrences (all)	0	0	4
Thrombocytopenia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	6 / 26 (23.08%)
occurrences (all)	0	0	16
Ear and labyrinth disorders			
Ear congestion			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Ear discomfort			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
Dry eye			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	1	0	0
Gastrointestinal disorders			
Abdominal distension			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 26 (3.85%)
occurrences (all)	0	0	1

Abdominal pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	2 / 26 (7.69%)
occurrences (all)	0	0	2
Abdominal pain upper			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 26 (3.85%)
occurrences (all)	0	0	1
Constipation			
subjects affected / exposed	1 / 3 (33.33%)	1 / 3 (33.33%)	10 / 26 (38.46%)
occurrences (all)	1	1	11
Diarrhoea			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	6 / 26 (23.08%)
occurrences (all)	0	0	6
Dyspepsia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	2 / 26 (7.69%)
occurrences (all)	0	0	2
Dysphagia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	2 / 26 (7.69%)
occurrences (all)	0	0	2
Enteritis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Flatulence			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Gastritis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Glossodynia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Haemorrhoids			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	1 / 26 (3.85%)
occurrences (all)	1	0	1
Ileus			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 26 (0.00%)
occurrences (all)	0	1	0

Mouth ulceration			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	1 / 3 (33.33%)	2 / 3 (66.67%)	6 / 26 (23.08%)
occurrences (all)	3	2	9
Pancreatitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 26 (3.85%)
occurrences (all)	0	0	1
Periodontal disease			
subjects affected / exposed	1 / 3 (33.33%)	1 / 3 (33.33%)	1 / 26 (3.85%)
occurrences (all)	1	1	1
Stomatitis			
subjects affected / exposed	1 / 3 (33.33%)	3 / 3 (100.00%)	5 / 26 (19.23%)
occurrences (all)	1	3	5
Vomiting			
subjects affected / exposed	1 / 3 (33.33%)	1 / 3 (33.33%)	4 / 26 (15.38%)
occurrences (all)	1	1	6
Hepatobiliary disorders			
Hepatic congestion			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Hepatic function abnormal			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	2 / 26 (7.69%)
occurrences (all)	0	0	3
Hepatosplenomegaly			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Hyperbilirubinaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Drug-Induced liver injury			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	1	0	0
Skin and subcutaneous tissue disorders			

Acute febrile neutrophilic dermatosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Dermatitis allergic			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 26 (0.00%)
occurrences (all)	0	1	0
Drug eruption			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	1	0	0
Dry skin			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Ecchymosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Erythema			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Petechiae			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	2 / 26 (7.69%)
occurrences (all)	0	0	2
Pruritus			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 26 (0.00%)
occurrences (all)	0	1	0
Rash			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	1	0	0
Rash maculo-papular			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	2 / 26 (7.69%)
occurrences (all)	0	0	3
Skin exfoliation			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Acute kidney injury			

subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	1 / 26 (3.85%)
occurrences (all)	1	0	1
Haematuria			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Renal tubular disorder			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Back pain			
subjects affected / exposed	2 / 3 (66.67%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	2	0	0
Bone pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Costochondritis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Joint swelling			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Muscular weakness			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal pain			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 26 (3.85%)
occurrences (all)	0	0	1
Neck pain			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 26 (3.85%)
occurrences (all)	0	0	1
Pain in extremity			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	1 / 26 (3.85%)
occurrences (all)	1	0	1
Polymyalgia rheumatica			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	1	0	0
Tendonitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Device related infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Gingivitis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Herpes simplex			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	1	0	0
Herpes zoster			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	1	0	0
Lung infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 26 (3.85%)
occurrences (all)	0	0	3
Oral candidiasis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 26 (3.85%)
occurrences (all)	0	0	1
Otitis media			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	1	0	0
Pneumonia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 26 (3.85%)
occurrences (all)	0	0	1

Sepsis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 26 (3.85%)
occurrences (all)	0	0	1
Skin infection			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	1	0	0
Subcutaneous abscess			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	1	0	0
Upper respiratory tract infection			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	1	0	0
Urinary tract infection			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	1 / 26 (3.85%)
occurrences (all)	0	0	2
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	3 / 26 (11.54%)
occurrences (all)	3	0	4
Dehydration			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	2 / 26 (7.69%)
occurrences (all)	1	0	2
Diabetes mellitus			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Fluid overload			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Glucose tolerance impaired			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 26 (0.00%)
occurrences (all)	0	1	0
Hyperglycaemia			
subjects affected / exposed	1 / 3 (33.33%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	1	0	0
Hyperkalaemia			

subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Hypermagnesaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Hypernatraemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	2 / 26 (7.69%)
occurrences (all)	0	0	2
Hypoalbuminaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	2 / 26 (7.69%)
occurrences (all)	0	0	2
Hypoglycaemia			
subjects affected / exposed	0 / 3 (0.00%)	1 / 3 (33.33%)	0 / 26 (0.00%)
occurrences (all)	0	1	0
Hypokalaemia			
subjects affected / exposed	1 / 3 (33.33%)	1 / 3 (33.33%)	1 / 26 (3.85%)
occurrences (all)	3	1	1
Hypomagnesaemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	3 / 26 (11.54%)
occurrences (all)	0	0	3
Hyponatraemia			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	2 / 26 (7.69%)
occurrences (all)	0	0	2
Metabolic acidosis			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	0 / 26 (0.00%)
occurrences (all)	0	0	0
Tumour lysis syndrome			
subjects affected / exposed	0 / 3 (0.00%)	0 / 3 (0.00%)	2 / 26 (7.69%)
occurrences (all)	0	0	2

Non-serious adverse events	Dose expansion: Ulocuplumab 1000mg + LDAC	Dose expansion: LDAC alone	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	14 / 14 (100.00%)	21 / 22 (95.45%)	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			

Acute myeloid leukaemia			
subjects affected / exposed	0 / 14 (0.00%)	3 / 22 (13.64%)	
occurrences (all)	0	3	
Vascular disorders			
Haematoma			
subjects affected / exposed	0 / 14 (0.00%)	1 / 22 (4.55%)	
occurrences (all)	0	2	
Haemorrhage			
subjects affected / exposed	1 / 14 (7.14%)	0 / 22 (0.00%)	
occurrences (all)	1	0	
Hypertension			
subjects affected / exposed	2 / 14 (14.29%)	1 / 22 (4.55%)	
occurrences (all)	2	1	
Hypotension			
subjects affected / exposed	1 / 14 (7.14%)	0 / 22 (0.00%)	
occurrences (all)	1	0	
Vasculitis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 22 (0.00%)	
occurrences (all)	0	0	
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 14 (0.00%)	2 / 22 (9.09%)	
occurrences (all)	0	2	
Catheter site erythema			
subjects affected / exposed	0 / 14 (0.00%)	0 / 22 (0.00%)	
occurrences (all)	0	0	
Chills			
subjects affected / exposed	3 / 14 (21.43%)	2 / 22 (9.09%)	
occurrences (all)	5	3	
Early satiety			
subjects affected / exposed	1 / 14 (7.14%)	0 / 22 (0.00%)	
occurrences (all)	1	0	
Fatigue			
subjects affected / exposed	4 / 14 (28.57%)	5 / 22 (22.73%)	
occurrences (all)	4	5	
Generalised oedema			

subjects affected / exposed	1 / 14 (7.14%)	0 / 22 (0.00%)	
occurrences (all)	1	0	
Malaise			
subjects affected / exposed	0 / 14 (0.00%)	1 / 22 (4.55%)	
occurrences (all)	0	1	
Mass			
subjects affected / exposed	1 / 14 (7.14%)	0 / 22 (0.00%)	
occurrences (all)	1	0	
Mucosal inflammation			
subjects affected / exposed	1 / 14 (7.14%)	1 / 22 (4.55%)	
occurrences (all)	1	1	
Oedema peripheral			
subjects affected / exposed	1 / 14 (7.14%)	4 / 22 (18.18%)	
occurrences (all)	1	8	
Pyrexia			
subjects affected / exposed	5 / 14 (35.71%)	5 / 22 (22.73%)	
occurrences (all)	7	9	
Non-Cardiac chest pain			
subjects affected / exposed	2 / 14 (14.29%)	0 / 22 (0.00%)	
occurrences (all)	2	0	
Immune system disorders			
Hypersensitivity			
subjects affected / exposed	2 / 14 (14.29%)	0 / 22 (0.00%)	
occurrences (all)	5	0	
Reproductive system and breast disorders			
Breast pain			
subjects affected / exposed	1 / 14 (7.14%)	0 / 22 (0.00%)	
occurrences (all)	1	0	
Genital ulceration			
subjects affected / exposed	1 / 14 (7.14%)	0 / 22 (0.00%)	
occurrences (all)	1	0	
Prostatitis			
subjects affected / exposed	0 / 14 (0.00%)	0 / 22 (0.00%)	
occurrences (all)	0	0	
Respiratory, thoracic and mediastinal disorders			

Cough			
subjects affected / exposed	3 / 14 (21.43%)	2 / 22 (9.09%)	
occurrences (all)	3	2	
Dyspnoea			
subjects affected / exposed	4 / 14 (28.57%)	1 / 22 (4.55%)	
occurrences (all)	5	1	
Dyspnoea exertional			
subjects affected / exposed	1 / 14 (7.14%)	0 / 22 (0.00%)	
occurrences (all)	1	0	
Epistaxis			
subjects affected / exposed	1 / 14 (7.14%)	0 / 22 (0.00%)	
occurrences (all)	1	0	
Hypoxia			
subjects affected / exposed	1 / 14 (7.14%)	0 / 22 (0.00%)	
occurrences (all)	1	0	
Interstitial lung disease			
subjects affected / exposed	1 / 14 (7.14%)	0 / 22 (0.00%)	
occurrences (all)	1	0	
Oropharyngeal pain			
subjects affected / exposed	2 / 14 (14.29%)	1 / 22 (4.55%)	
occurrences (all)	2	1	
Pleural effusion			
subjects affected / exposed	1 / 14 (7.14%)	1 / 22 (4.55%)	
occurrences (all)	1	1	
Productive cough			
subjects affected / exposed	0 / 14 (0.00%)	0 / 22 (0.00%)	
occurrences (all)	0	0	
Rhinorrhoea			
subjects affected / exposed	2 / 14 (14.29%)	0 / 22 (0.00%)	
occurrences (all)	2	0	
Stridor			
subjects affected / exposed	1 / 14 (7.14%)	0 / 22 (0.00%)	
occurrences (all)	1	0	
Upper respiratory tract inflammation			
subjects affected / exposed	1 / 14 (7.14%)	0 / 22 (0.00%)	
occurrences (all)	1	0	

Wheezing			
subjects affected / exposed	2 / 14 (14.29%)	1 / 22 (4.55%)	
occurrences (all)	2	1	
Psychiatric disorders			
Adjustment disorder with depressed mood			
subjects affected / exposed	1 / 14 (7.14%)	0 / 22 (0.00%)	
occurrences (all)	1	0	
Anxiety			
subjects affected / exposed	2 / 14 (14.29%)	0 / 22 (0.00%)	
occurrences (all)	2	0	
Confusional state			
subjects affected / exposed	0 / 14 (0.00%)	0 / 22 (0.00%)	
occurrences (all)	0	0	
Delirium			
subjects affected / exposed	1 / 14 (7.14%)	0 / 22 (0.00%)	
occurrences (all)	1	0	
Insomnia			
subjects affected / exposed	1 / 14 (7.14%)	1 / 22 (4.55%)	
occurrences (all)	1	1	
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	1 / 14 (7.14%)	2 / 22 (9.09%)	
occurrences (all)	1	2	
Amylase increased			
subjects affected / exposed	0 / 14 (0.00%)	0 / 22 (0.00%)	
occurrences (all)	0	0	
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 14 (0.00%)	0 / 22 (0.00%)	
occurrences (all)	0	0	
Blood alkaline phosphatase increased			
subjects affected / exposed	1 / 14 (7.14%)	1 / 22 (4.55%)	
occurrences (all)	1	1	
Blood bilirubin increased			
subjects affected / exposed	1 / 14 (7.14%)	0 / 22 (0.00%)	
occurrences (all)	1	0	
Blood creatine phosphokinase			

increased			
subjects affected / exposed	1 / 14 (7.14%)	0 / 22 (0.00%)	
occurrences (all)	1	0	
Blood creatinine increased			
subjects affected / exposed	1 / 14 (7.14%)	0 / 22 (0.00%)	
occurrences (all)	1	0	
Lipase increased			
subjects affected / exposed	0 / 14 (0.00%)	2 / 22 (9.09%)	
occurrences (all)	0	2	
Neutrophil count decreased			
subjects affected / exposed	1 / 14 (7.14%)	6 / 22 (27.27%)	
occurrences (all)	1	15	
Platelet count decreased			
subjects affected / exposed	4 / 14 (28.57%)	8 / 22 (36.36%)	
occurrences (all)	5	18	
Weight decreased			
subjects affected / exposed	0 / 14 (0.00%)	2 / 22 (9.09%)	
occurrences (all)	0	2	
White blood cell count decreased			
subjects affected / exposed	1 / 14 (7.14%)	3 / 22 (13.64%)	
occurrences (all)	1	15	
C-Reactive protein increased			
subjects affected / exposed	0 / 14 (0.00%)	2 / 22 (9.09%)	
occurrences (all)	0	2	
Electrocardiogram qt prolonged			
subjects affected / exposed	1 / 14 (7.14%)	0 / 22 (0.00%)	
occurrences (all)	1	0	
Troponin t increased			
subjects affected / exposed	1 / 14 (7.14%)	0 / 22 (0.00%)	
occurrences (all)	1	0	
Injury, poisoning and procedural complications			
Allergic transfusion reaction			
subjects affected / exposed	0 / 14 (0.00%)	0 / 22 (0.00%)	
occurrences (all)	0	0	
Compression fracture			

subjects affected / exposed	1 / 14 (7.14%)	0 / 22 (0.00%)	
occurrences (all)	1	0	
Fall			
subjects affected / exposed	0 / 14 (0.00%)	2 / 22 (9.09%)	
occurrences (all)	0	2	
Infusion related reaction			
subjects affected / exposed	2 / 14 (14.29%)	2 / 22 (9.09%)	
occurrences (all)	3	2	
Procedural pain			
subjects affected / exposed	1 / 14 (7.14%)	0 / 22 (0.00%)	
occurrences (all)	1	0	
Transfusion reaction			
subjects affected / exposed	1 / 14 (7.14%)	0 / 22 (0.00%)	
occurrences (all)	1	0	
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 14 (0.00%)	0 / 22 (0.00%)	
occurrences (all)	0	0	
Cardiac failure			
subjects affected / exposed	0 / 14 (0.00%)	3 / 22 (13.64%)	
occurrences (all)	0	3	
Tachycardia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 22 (0.00%)	
occurrences (all)	0	0	
Nervous system disorders			
Dizziness			
subjects affected / exposed	0 / 14 (0.00%)	2 / 22 (9.09%)	
occurrences (all)	0	2	
Headache			
subjects affected / exposed	3 / 14 (21.43%)	2 / 22 (9.09%)	
occurrences (all)	6	2	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	3 / 14 (21.43%)	8 / 22 (36.36%)	
occurrences (all)	4	15	
Febrile neutropenia			

subjects affected / exposed	4 / 14 (28.57%)	7 / 22 (31.82%)	
occurrences (all)	4	9	
Increased tendency to bruise			
subjects affected / exposed	1 / 14 (7.14%)	0 / 22 (0.00%)	
occurrences (all)	1	0	
Leukocytosis			
subjects affected / exposed	1 / 14 (7.14%)	1 / 22 (4.55%)	
occurrences (all)	1	1	
Neutropenia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 22 (0.00%)	
occurrences (all)	0	0	
Thrombocytopenia			
subjects affected / exposed	0 / 14 (0.00%)	2 / 22 (9.09%)	
occurrences (all)	0	2	
Ear and labyrinth disorders			
Ear congestion			
subjects affected / exposed	1 / 14 (7.14%)	0 / 22 (0.00%)	
occurrences (all)	1	0	
Ear discomfort			
subjects affected / exposed	1 / 14 (7.14%)	0 / 22 (0.00%)	
occurrences (all)	1	0	
Eye disorders			
Dry eye			
subjects affected / exposed	0 / 14 (0.00%)	0 / 22 (0.00%)	
occurrences (all)	0	0	
Gastrointestinal disorders			
Abdominal distension			
subjects affected / exposed	1 / 14 (7.14%)	2 / 22 (9.09%)	
occurrences (all)	1	2	
Abdominal pain			
subjects affected / exposed	1 / 14 (7.14%)	1 / 22 (4.55%)	
occurrences (all)	1	1	
Abdominal pain upper			
subjects affected / exposed	1 / 14 (7.14%)	0 / 22 (0.00%)	
occurrences (all)	1	0	
Constipation			

subjects affected / exposed	2 / 14 (14.29%)	5 / 22 (22.73%)	
occurrences (all)	2	6	
Diarrhoea			
subjects affected / exposed	3 / 14 (21.43%)	5 / 22 (22.73%)	
occurrences (all)	3	6	
Dyspepsia			
subjects affected / exposed	0 / 14 (0.00%)	1 / 22 (4.55%)	
occurrences (all)	0	1	
Dysphagia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 22 (0.00%)	
occurrences (all)	0	0	
Enteritis			
subjects affected / exposed	1 / 14 (7.14%)	0 / 22 (0.00%)	
occurrences (all)	1	0	
Flatulence			
subjects affected / exposed	1 / 14 (7.14%)	0 / 22 (0.00%)	
occurrences (all)	1	0	
Gastritis			
subjects affected / exposed	1 / 14 (7.14%)	1 / 22 (4.55%)	
occurrences (all)	1	1	
Glossodynia			
subjects affected / exposed	1 / 14 (7.14%)	0 / 22 (0.00%)	
occurrences (all)	1	0	
Haemorrhoids			
subjects affected / exposed	1 / 14 (7.14%)	2 / 22 (9.09%)	
occurrences (all)	1	2	
Ileus			
subjects affected / exposed	0 / 14 (0.00%)	0 / 22 (0.00%)	
occurrences (all)	0	0	
Mouth ulceration			
subjects affected / exposed	2 / 14 (14.29%)	1 / 22 (4.55%)	
occurrences (all)	2	1	
Nausea			
subjects affected / exposed	8 / 14 (57.14%)	6 / 22 (27.27%)	
occurrences (all)	11	9	
Pancreatitis			

subjects affected / exposed	1 / 14 (7.14%)	1 / 22 (4.55%)	
occurrences (all)	1	1	
Periodontal disease			
subjects affected / exposed	0 / 14 (0.00%)	0 / 22 (0.00%)	
occurrences (all)	0	0	
Stomatitis			
subjects affected / exposed	3 / 14 (21.43%)	4 / 22 (18.18%)	
occurrences (all)	5	6	
Vomiting			
subjects affected / exposed	1 / 14 (7.14%)	3 / 22 (13.64%)	
occurrences (all)	1	3	
Hepatobiliary disorders			
Hepatic congestion			
subjects affected / exposed	1 / 14 (7.14%)	0 / 22 (0.00%)	
occurrences (all)	1	0	
Hepatic function abnormal			
subjects affected / exposed	0 / 14 (0.00%)	1 / 22 (4.55%)	
occurrences (all)	0	1	
Hepatosplenomegaly			
subjects affected / exposed	1 / 14 (7.14%)	0 / 22 (0.00%)	
occurrences (all)	1	0	
Hyperbilirubinaemia			
subjects affected / exposed	1 / 14 (7.14%)	1 / 22 (4.55%)	
occurrences (all)	1	1	
Drug-Induced liver injury			
subjects affected / exposed	0 / 14 (0.00%)	0 / 22 (0.00%)	
occurrences (all)	0	0	
Skin and subcutaneous tissue disorders			
Acute febrile neutrophilic dermatosis			
subjects affected / exposed	0 / 14 (0.00%)	2 / 22 (9.09%)	
occurrences (all)	0	2	
Dermatitis allergic			
subjects affected / exposed	0 / 14 (0.00%)	0 / 22 (0.00%)	
occurrences (all)	0	0	
Drug eruption			

subjects affected / exposed	0 / 14 (0.00%)	0 / 22 (0.00%)	
occurrences (all)	0	0	
Dry skin			
subjects affected / exposed	1 / 14 (7.14%)	1 / 22 (4.55%)	
occurrences (all)	1	1	
Ecchymosis			
subjects affected / exposed	1 / 14 (7.14%)	2 / 22 (9.09%)	
occurrences (all)	1	2	
Erythema			
subjects affected / exposed	2 / 14 (14.29%)	1 / 22 (4.55%)	
occurrences (all)	2	1	
Petechiae			
subjects affected / exposed	2 / 14 (14.29%)	0 / 22 (0.00%)	
occurrences (all)	2	0	
Pruritus			
subjects affected / exposed	1 / 14 (7.14%)	1 / 22 (4.55%)	
occurrences (all)	1	1	
Rash			
subjects affected / exposed	3 / 14 (21.43%)	2 / 22 (9.09%)	
occurrences (all)	3	2	
Rash maculo-papular			
subjects affected / exposed	1 / 14 (7.14%)	2 / 22 (9.09%)	
occurrences (all)	1	3	
Skin exfoliation			
subjects affected / exposed	1 / 14 (7.14%)	0 / 22 (0.00%)	
occurrences (all)	1	0	
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	1 / 14 (7.14%)	0 / 22 (0.00%)	
occurrences (all)	1	0	
Haematuria			
subjects affected / exposed	1 / 14 (7.14%)	0 / 22 (0.00%)	
occurrences (all)	1	0	
Renal tubular disorder			
subjects affected / exposed	1 / 14 (7.14%)	0 / 22 (0.00%)	
occurrences (all)	1	0	

Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	1 / 14 (7.14%)	2 / 22 (9.09%)	
occurrences (all)	1	2	
Back pain			
subjects affected / exposed	4 / 14 (28.57%)	0 / 22 (0.00%)	
occurrences (all)	4	0	
Bone pain			
subjects affected / exposed	1 / 14 (7.14%)	0 / 22 (0.00%)	
occurrences (all)	2	0	
Costochondritis			
subjects affected / exposed	1 / 14 (7.14%)	0 / 22 (0.00%)	
occurrences (all)	1	0	
Joint swelling			
subjects affected / exposed	1 / 14 (7.14%)	0 / 22 (0.00%)	
occurrences (all)	1	0	
Muscular weakness			
subjects affected / exposed	1 / 14 (7.14%)	0 / 22 (0.00%)	
occurrences (all)	1	0	
Musculoskeletal chest pain			
subjects affected / exposed	1 / 14 (7.14%)	0 / 22 (0.00%)	
occurrences (all)	1	0	
Musculoskeletal pain			
subjects affected / exposed	1 / 14 (7.14%)	1 / 22 (4.55%)	
occurrences (all)	1	1	
Neck pain			
subjects affected / exposed	2 / 14 (14.29%)	1 / 22 (4.55%)	
occurrences (all)	2	1	
Pain in extremity			
subjects affected / exposed	0 / 14 (0.00%)	0 / 22 (0.00%)	
occurrences (all)	0	0	
Polymyalgia rheumatica			
subjects affected / exposed	0 / 14 (0.00%)	0 / 22 (0.00%)	
occurrences (all)	0	0	
Tendonitis			

subjects affected / exposed	1 / 14 (7.14%)	0 / 22 (0.00%)	
occurrences (all)	1	0	
Infections and infestations			
Device related infection			
subjects affected / exposed	0 / 14 (0.00%)	2 / 22 (9.09%)	
occurrences (all)	0	2	
Gingivitis			
subjects affected / exposed	2 / 14 (14.29%)	0 / 22 (0.00%)	
occurrences (all)	2	0	
Herpes simplex			
subjects affected / exposed	0 / 14 (0.00%)	0 / 22 (0.00%)	
occurrences (all)	0	0	
Herpes zoster			
subjects affected / exposed	0 / 14 (0.00%)	0 / 22 (0.00%)	
occurrences (all)	0	0	
Lung infection			
subjects affected / exposed	1 / 14 (7.14%)	3 / 22 (13.64%)	
occurrences (all)	1	3	
Oral candidiasis			
subjects affected / exposed	1 / 14 (7.14%)	2 / 22 (9.09%)	
occurrences (all)	1	2	
Otitis media			
subjects affected / exposed	0 / 14 (0.00%)	0 / 22 (0.00%)	
occurrences (all)	0	0	
Pneumonia			
subjects affected / exposed	1 / 14 (7.14%)	1 / 22 (4.55%)	
occurrences (all)	1	1	
Sepsis			
subjects affected / exposed	1 / 14 (7.14%)	0 / 22 (0.00%)	
occurrences (all)	1	0	
Skin infection			
subjects affected / exposed	0 / 14 (0.00%)	1 / 22 (4.55%)	
occurrences (all)	0	2	
Subcutaneous abscess			
subjects affected / exposed	0 / 14 (0.00%)	0 / 22 (0.00%)	
occurrences (all)	0	0	

Upper respiratory tract infection			
subjects affected / exposed	0 / 14 (0.00%)	1 / 22 (4.55%)	
occurrences (all)	0	1	
Urinary tract infection			
subjects affected / exposed	1 / 14 (7.14%)	2 / 22 (9.09%)	
occurrences (all)	1	3	
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	2 / 14 (14.29%)	4 / 22 (18.18%)	
occurrences (all)	2	5	
Dehydration			
subjects affected / exposed	0 / 14 (0.00%)	1 / 22 (4.55%)	
occurrences (all)	0	1	
Diabetes mellitus			
subjects affected / exposed	1 / 14 (7.14%)	0 / 22 (0.00%)	
occurrences (all)	1	0	
Fluid overload			
subjects affected / exposed	1 / 14 (7.14%)	0 / 22 (0.00%)	
occurrences (all)	1	0	
Glucose tolerance impaired			
subjects affected / exposed	0 / 14 (0.00%)	1 / 22 (4.55%)	
occurrences (all)	0	1	
Hyperglycaemia			
subjects affected / exposed	0 / 14 (0.00%)	2 / 22 (9.09%)	
occurrences (all)	0	2	
Hyperkalaemia			
subjects affected / exposed	1 / 14 (7.14%)	2 / 22 (9.09%)	
occurrences (all)	1	2	
Hypermagnesaemia			
subjects affected / exposed	1 / 14 (7.14%)	0 / 22 (0.00%)	
occurrences (all)	1	0	
Hypernatraemia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 22 (0.00%)	
occurrences (all)	0	0	
Hypoalbuminaemia			

subjects affected / exposed	1 / 14 (7.14%)	1 / 22 (4.55%)	
occurrences (all)	1	1	
Hypoglycaemia			
subjects affected / exposed	1 / 14 (7.14%)	0 / 22 (0.00%)	
occurrences (all)	1	0	
Hypokalaemia			
subjects affected / exposed	3 / 14 (21.43%)	3 / 22 (13.64%)	
occurrences (all)	3	7	
Hypomagnesaemia			
subjects affected / exposed	0 / 14 (0.00%)	0 / 22 (0.00%)	
occurrences (all)	0	0	
Hyponatraemia			
subjects affected / exposed	2 / 14 (14.29%)	1 / 22 (4.55%)	
occurrences (all)	2	1	
Metabolic acidosis			
subjects affected / exposed	1 / 14 (7.14%)	1 / 22 (4.55%)	
occurrences (all)	1	1	
Tumour lysis syndrome			
subjects affected / exposed	0 / 14 (0.00%)	0 / 22 (0.00%)	
occurrences (all)	0	0	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
24 October 2014	This amendment of the protocol is in response to the 30-day review by Pharmaceuticals and Medical Devices Association (PMDA) for Clinical Trial Notification. Additional changes for a clarification purpose are also incorporated in this amendment.
07 May 2015	This amendment of the protocol is to implement following changes: modify the target population to remove the restriction on AML (newly diagnosed, elderly), extend the period of contraception use, modify prior therapy related criteria, and modify hepatitis B and C infection criteria to only exclude active infection. This amendment is also to change Medical Monitor.
02 November 2016	This amendment expands the study globally to provide insights of safety and efficacy of two different dose levels of ulocuplumab (800 mg and 1000 mg) in combination with low dose cytarabine (LDAC) and LDAC alone for the treatment of Acute Myeloid Leukemia (AML). The expansion will enroll subjects (18 years old) with newly diagnosed AML that are unfit for high induction chemotherapy or stem cell transplant because of age or comorbidities. The changes include addition of a Phase 2 (expansion cohort) with 1:1:1 randomization of approximately 120 subjects, 40 subjects per treatment group, to assess preliminary efficacy by complete remission with blast count reduction 5% (CR) or complete remission with incomplete blood count recovery (CRi) and overall survival (OS). The changes include collection of samples for exploratory biomarker assessment such as CXR4, receptor occupancy and evaluation of ulocuplumab pharmacokinetics and interaction with LDAC. For safety, DLTs will be evaluated and ECG evaluation was added for a subset of subjects to measure QT intervals by Fridericia method.
10 February 2017	This amendment implements the following changes: revises the telephone/fax numbers and location of the BMS Medical Monitor; corrects study title in synopsis; clarifies that exclusion criterion 2b is applicable; clarifies dose modifications and addition of ulocuplumab to LDAC alone arm; clarifies local lab bone marrow results sent to BMS; clarifies standard of care testing for extramedullary disease; adds central lab cytogenetic testing; deletes local cytogenetic testing; clarifies time point for end of cycle leukemia assessment; clarifies bone marrow aspirate is sufficient for leukemia evaluation; reduces pregnancy test requirement (WOBCP) to once per cycle and monthly during dose delays; adds pregnancy test to EOT; clarifies and/or corrects Time and Events Schedule footnotes; clarifies hematology blast percentage is included in hematology lab tests; clarifies PK, ADA, and receptor occupancy samples are not collected for subjects randomized to the LDAC alone arm; clarifies footnotes in PK and biomarker tables; clarifies safety and serial ECG requirements; provides details of biomarker testing; Appendices 1 and 3 updated.
29 March 2017	This amendment implements the following changes: revises synopsis to align with revisions in sections 3.1, 8.3.1 and 8.3.2; revises study design description; revises study treatment and dose timing sections to clarify when LDAC only arm may add ulocuplumab; revises discontinuation, dose modifications, infusion delays, and missed doses sections; adds whole exome sequencing to bone marrow and peripheral blood biomarker testing; revises Tables 5.1-2, 5.1-3, 5.7.2-1; moves cytogenetic testing to other assessments section; adds ECG analyses section; adds whole exome sequencing to biomarker analyses section; revises primary endpoint analysis details; revises secondary endpoint details; moves ECG analyses details from biomarker analyses section to a new section; adds cytogenetic analyses section.

27 July 2017	The exclusion criteria was revised to specify allogeneic transplants in participants who received prior hematopoietic stem cell transplantation The schedule for the collection of hematology samples during treatment cycles 1 and 2 was revised to eliminate the requirement for 10 days consecutive days of hematology collections, and to allow hematology sample collection flexibility up to 72 hours before infusion of ulocuplumab Peripheral blood and serum/plasma collection criteria during End of study treatment and follow-up assessment were revised from mandatory status to include exceptions listed in Section 5.7.2 and Table 5.7.2 1 Buccal swab procedure was added to treatment procedural outline and biomarkers sampling schedule for the expansion cohort Time and assessment ranges were revised to reflect current standards in Sections 4.6.1.1 and 4.6.1.2 and Table 4.6.1.2-1 Removed bone marrow collection for TCR sequencing.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? Yes

Date	Interruption	Restart date
04 June 2019	The preliminary efficacy results for the Phase 2 cohort, analyzed at a pre-planned interim analysis, did not replicate the activity observed in Phase 1, with results below the expected clinical benefit from current treatment options. Based on these findings during the pre-specified interim analysis, the enrollment was terminated and the trial was discontinued.	-

Notes:

Limitations and caveats

None reported